Description
General description
Matrix metalloproteinases (MMPs) are a family of enzymes that are responsible for the degradation of extracellular matrix components such as collagen, laminin and proteoglycans. In addition to sequence homology, all MMPs share the following characteristics: the catalytic mechanism is dependent upon a zinc ion at the active center, they cleave one or more extracellular matrix components, they are secreted as zymogens which are activated by removal of an ~10 kDa segment from the N-terminus and they are inhibited by tissue inhibitor of metalloproteinases (TIMP). These enzymes are involved in normal physiological processes such as embryogenesis and tissue remodeling and may play an important role in arthritis, periodontitis, and metastasis.MMP-1 (interstitial collagenase, tissue collagenase, fibroblast collagenase) is secreted as a 57/52 kDa zymogen which is proteolytically processed to the 46/42 kDa active forms. This enzyme displays substrate specificity toward type I, II, III, VII, VIII and X collagens and gelatin. MMP-1 is thought to play an important role in pathophysiological degradation processes associated with conditions such as rheumatoid arthritis, osteoarthritis, and cancer cell invasion.
Purified mouse monoclonal antibody. Recognizes the ~55 kDa latent and the ~43 kDa active forms of MMP-1.
Recognizes the ~55 kDa latent and the ~43 kDa active forms of MMP-1.
Immunogen
Human
a synthetic peptide (VQGQNVLHGYPKDIYSSFG) corresponding to amino acids 332-350 of human MMP-1
Application
Frozen sections (see application references)
Immunoblotting (1 g/ml)
Paraffin sections (2.5 g/ml, pressure cooker pre-treatment required)
Packaging
Please refer to vial label for lot-specific concentration.
Physical form
In 100 mM sodium phosphate buffer, 0.1% BSA, pH 7.0
Preparation Note
Following initial thaw, aliquot and freeze (-20°C).
Other Notes
Cottam, D.W. and Rees, R.C. 1993. Intl. J. Oncol.2, 861.
Stetler-Stevenson, W.G., et al. 1993. FASEB7, 1434.
Zhang, J., et al. 1993. Clinica Chimica Acta.219, 1.
Woessner, J.F. 1991. FASEB5, 2145.
Liotta, L.A. and Stetler-Stevenson, W.G. 1990. in Seminars in Cancer Biology, ed. M. M. Gottesman. Vol. 1; 99-106.
To prepare conditioned medium for positive control, incubate HT-1080 cells for 2 h at 37°C in serum-free media containing 100 nM PMA. Collect and centrifuge medium; concentrate as necessary. Does not cross-react with bovine. Will not cross-react with human MMP-2, MMP-3, MMP-8, MMP-9, or MMP-13. For best results with paraffin sections, pre-treat with a pressure cooker; however, heat, saponin or trypsin can be used in place of a pressure cooker. Antibody should be titrated for optimal results in individual systems.
Legal Information
Manufactured by Daiichi Fine Chemical Co., Ltd. Not available for sale in Japan.
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
